Literature DB >> 30705115

The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?

Antonia M S Müller1, Shaji K Kumar2, Benedetto Bruno3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30705115      PMCID： PMC6355504          DOI： 10.3324/haematol.2018.206987

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  25 in total

1.  Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.

Authors:  M Ladetto; S Ferrero; D Drandi; M Festuccia; F Patriarca; N Mordini; S Cena; R Benedetto; G Guarona; F Ferrando; L Brunello; P Ghione; V Boccasavia; R Fanin; P Omedè; L Giaccone; A Palumbo; R Passera; M Boccadoro; B Bruno
Journal:  Leukemia       Date:  2015-10-06       Impact factor: 11.528

2.  Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.

Authors:  Philippe Moreau; Frédéric Garban; Michel Attal; Mauricette Michallet; Gérald Marit; Cyrille Hulin; Lotfi Benboubker; Chantal Doyen; Mohamad Mohty; Ibrahim Yakoub-Agha; Serge Leyvraz; Philippe Casassus; Hervé Avet-Loiseau; Laurent Garderet; Claire Mathiot; Jean-Luc Harousseau
Journal:  Blood       Date:  2008-11-01       Impact factor: 22.113

3.  Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

Authors:  Gösta Gahrton; Simona Iacobelli; Bo Björkstrand; Ute Hegenbart; Astrid Gruber; Hildegard Greinix; Liisa Volin; Franco Narni; Angelo Michele Carella; Meral Beksac; Alberto Bosi; Giuseppe Milone; Paolo Corradini; Stefan Schönland; Kristina Friberg; Anja van Biezen; Hartmut Goldschmidt; Theo de Witte; Curly Morris; Dietger Niederwieser; Laurent Garderet; Nicolaus Kröger
Journal:  Blood       Date:  2013-03-12       Impact factor: 22.113

4.  Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Authors:  Nicolaus Kröger; Anita Badbaran; Tatjana Zabelina; Francis Ayuk; Christine Wolschke; Haefaa Alchalby; Evgeny Klyuchnikov; Djordje Atanackovic; Georgia Schilling; Timon Hansen; Sabine Schwarz; Marion Heinzelmann; Silke Zeschke; Ulrike Bacher; Thomas Stübig; Boris Fehse; Axel R Zander
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-16       Impact factor: 5.742

5.  Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.

Authors:  Myo Htut; Anita D'Souza; Amrita Krishnan; Benedetto Bruno; Mei-Jie Zhang; Mingwei Fei; Miguel Angel Diaz; Edward Copelan; Siddhartha Ganguly; Mehdi Hamadani; Mohamed Kharfan-Dabaja; Hillard Lazarus; Cindy Lee; Kenneth Meehan; Taiga Nishihori; Ayman Saad; Sachiko Seo; Muthalagu Ramanathan; Saad Z Usmani; Christina Gasparetto; Tomer M Mark; Yago Nieto; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-24       Impact factor: 5.742

6.  Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

Authors:  N Kröger; T Zabelina; E Klyuchnikov; M Kropff; K-H Pflüger; A Burchert; T Stübig; C Wolschke; F Ayuk; Y Hildebrandt; U Bacher; A Badbaran; G Schilling; T Hansen; D Atanackovic; A R Zander
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

7.  Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.

Authors:  Luisa Giaccone; Andrea Evangelista; Francesca Patriarca; Roberto Sorasio; Massimo Pini; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Francesco Zallio; Enrico Maffini; Paola Omedé; Sara Bringhen; Nicola Mordini; Renato Fanin; Giovannino Ciccone; Mario Boccadoro; Benedetto Bruno
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-04       Impact factor: 5.742

8.  A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.

Authors:  Monika Engelhardt; Anne-Saskia Domm; Sandra Maria Dold; Gabriele Ihorst; Heike Reinhardt; Alexander Zober; Stefanie Hieke; Corine Baayen; Stefan Jürgen Müller; Hermann Einsele; Pieter Sonneveld; Ola Landgren; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

9.  Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.

Authors:  Enrico Maffini; Barry E Storer; Brenda M Sandmaier; Benedetto Bruno; Firoozeh Sahebi; Judith A Shizuru; Thomas R Chauncey; Parameswaran Hari; Thoralf Lange; Michael A Pulsipher; Peter A McSweeney; Leona Holmberg; Pamela S Becker; Damian J Green; Marco Mielcarek; David G Maloney; Rainer Storb
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

10.  Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Authors:  Christine Greil; Monika Engelhardt; Gabriele Ihorst; Katja Schoeller; Hartmut Bertz; Reinhard Marks; Robert Zeiser; Justus Duyster; Hermann Einsele; Jürgen Finke; Ralph Wäsch
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.